Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

Por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Berry, D A, Islam, R, Theriault, R L, Hortobagyi, G N, Ueno, N T
Publicado em 2010

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients

Por Cheng, Y C, Valero, V, Davis, M L, Green, M C, Gonzalez-Angulo, A M, Theriault, R L, Murray, J L, Hortobagyi, G N, Ueno, N T
Publicado em 2010

The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers

Por Brewster, A.M., Etzel, C., Zhou, R., Wong, Y., Edge, S., Blayney, D.W, Wilson, J., Hudis, C., Ottesen, R., Hughes, M.E., Weeks, J.C., Theriault, R.L.
Publicado em 2011

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer

Por Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W. F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R. L., Kiesel, L., Hortobagyi, G. N., Pusztai, L., Gonzalez-Angulo, A. M.
Publicado em 2009